Table 1.

Clinical trials of IDO-inhibitors

Strategy	Drug	Trial design	Trial number
Combination with chemotherapy	indoximod	combination with taxane in breast cancer	NCT01792050
	indoximod	combination with temozolomide ± radiation in refractory glioblastoma brain tumors	NCT02052648
	indoximod	combination with temozolomide ± radiation in pediatric brain tumors	NCT02502708
	indoximod	combination with gemcitabine + abraxane in pancreatic cancer	NCT02077881
	epacadostat	combination with targeted Jak1 inhibitor or PI3Kδ inhibitor	NCT02559492
Combination with checkpoint inhibitors	epacadostat	combination with anti-CTLA-4 (ipilimumab)	NCT01604889
	indoximod	combination with anti-CTLA-4 (ipilimumab)	NCT02073123
	epacadostat	combination with anti-PD-1 (pembrolizumab)	NCT02178722
	epacadostat	combination with anti-PD-L1 (atezolizumab)	NCT02298153
	epacadostat	combination with anti-PD-L1 (MEDI4736)	NCT02318277
	GDC-0919	combination with anti-PD-L1 (atezolizumab)	NCT02471846
Combination with vaccines	epacadostat	combination with NY-ESO-1 based vaccine in ovarian cancer	NCT02166905
	indoximod	combination with Hyperacute vaccine + docetaxel in lung cancer	NCT02460367
	epacadostat	combination with melanoma peptide vaccine	NCT01961115
	epacadostat	combination with Listeria-based mesothelin vaccine in ovarian cancer	NCT02575807